BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 18989889)

  • 1. Phase I study of paclitaxel with standard dose ifosfamide in children with refractory solid tumors: a Pediatric Oncology Group study (POG 9376).
    Geller JI; Wall D; Perentesis J; Blaney SM; Bernstein M;
    Pediatr Blood Cancer; 2009 Mar; 52(3):346-50. PubMed ID: 18989889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I trial of paclitaxel in children with refractory solid tumors: a Pediatric Oncology Group Study.
    Hurwitz CA; Relling MV; Weitman SD; Ravindranath Y; Vietti TJ; Strother DR; Ragab AH; Pratt CB
    J Clin Oncol; 1993 Dec; 11(12):2324-9. PubMed ID: 7902425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I study of ifosfamide, paclitaxel, and carboplatin in advanced and recurrent cervical cancer.
    Downs LS; Judson PL; Argenta PA; Carson LF; Boente MP
    Gynecol Oncol; 2004 Nov; 95(2):347-51. PubMed ID: 15491756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paclitaxel by 72-hour continuous infusion followed by bolus intravenous ifosfamide or epirubicin: results of two phase I studies.
    Miglietta L; Marenghi C; Nizzo R; Foglia G; Ragni N; Boccardo F
    Oncology; 2001; 60(2):116-22. PubMed ID: 11244325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Phase I trial of ifosfamide and paclitaxel with granulocyte-colony stimulating factor in the treatment of patients with refractory solid tumors.
    Bunnell CA; Thompson L; Buswell L; Berkowitz R; Muto M; Sheets E; Shulman LN
    Cancer; 1998 Feb; 82(3):561-6. PubMed ID: 9452275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Docetaxel, ifosfamide and cisplatin in solid tumour treatment: a phase I study.
    Specenier P; Rasschaert M; Van den Brande J; Dyck J; Schrijvers D; Huizing MT; Vermorken JB
    Anticancer Drugs; 2010 Mar; 21(3):306-12. PubMed ID: 20087171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I study of dose-escalated paclitaxel, ifosfamide, and cisplatin (PIC) combination chemotherapy in advanced solid tumours.
    Kosmas C; Tsavaris NB; Polyzos A; Malamos NA; Katsikas M; Antonopoulos MJ
    Br J Cancer; 2000 Jan; 82(2):300-7. PubMed ID: 10646881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I clinical and pharmacokinetic study of combination chemotherapy with topotecan and ifosfamide in patients with progressive or relapsed solid tumors.
    Schneider CP; Merkel U; Grübner U; Kath R; Höffken K; Hoffmann A
    J Cancer Res Clin Oncol; 2002 Jun; 128(6):313-8. PubMed ID: 12073049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I and pharmacokinetic study of losoxantrone and paclitaxel in patients with advanced solid tumors.
    Diab SG; Baker SD; Joshi A; Burris HA; Cobb PW; Villalona-Calero MA; Eckhardt SG; Weiss GR; Rodriguez GI; Drengler R; Kraynak M; Hammond L; Finizio M; Von Hoff DD; Rowinsky EK
    Clin Cancer Res; 1999 Feb; 5(2):299-308. PubMed ID: 10037178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I clinical, pharmacological, and biological trial of interleukin 6 plus granulocyte-colony stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent/refractory solid tumors: enhanced hematological responses but a high incidence of grade III/IV constitutional toxicities.
    Bracho F; Krailo MD; Shen V; Bergeron S; Davenport V; Liu-Mares W; Blazar BR; Panoskaltsis-Mortari A; van de Ven C; Secola R; Ames MM; Reid JM; Reaman GH; Cairo MS
    Clin Cancer Res; 2001 Jan; 7(1):58-67. PubMed ID: 11205919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I and pharmacokinetic study of polymeric micelle‑formulated paclitaxel in adult Chinese patients with advanced solid tumors.
    Lv F; Cao J; Zhang J; Qian J; Peng W; Sun S; Li W; Zhang W; Guo W; Li J
    Cancer Chemother Pharmacol; 2014 Jun; 73(6):1173-9. PubMed ID: 24658629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck.
    Shin DM; Glisson BS; Khuri FR; Lippman SM; Ginsberg L; Diaz E; Papadimitrakopoulou V; Feng L; Francisco M; Garden A; Kies MS; Myers J; Clayman G; Hong WK
    Cancer; 2002 Jul; 95(2):322-30. PubMed ID: 12124833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I dose-escalation trial of paclitaxel and ifosfamide in patients with advanced non-small cell lung cancer.
    Shepherd FA; Latreille J; Paul K; Eisenhauer E
    Semin Oncol; 1996 Dec; 23(6 Suppl 16):84-90. PubMed ID: 9007130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paclitaxel and ifosfamide: a multicenter phase I study in advanced non-small cell lung cancer.
    Hoffman PC; Krauss SA; Drinkard LC; Masters GA; Samuels BL; Bitran JD; Golomb HM; Watson S; Vokes EE
    Semin Oncol; 1995 Aug; 22(4 Suppl 9):38-41. PubMed ID: 7544026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I trial of ifosfamide and 24-h infusional paclitaxel in pelvic malignancies: a Gynecologic Oncology Group study.
    Markman M; Spriggs D; Burger RA; Carson LF; Lentz SS; Gallion H
    Gynecol Oncol; 2001 Mar; 80(3):359-63. PubMed ID: 11263932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I study of ifosfamide/carboplatin/etoposide/paclitaxel in advanced lung cancer.
    Strauss GM; Lynch TJ; Elias AD; Jacobs C; Kwiatkowski DJ; Shulman LN; Carey RW; Grossbard ML; Jauss S; Sugarbaker DJ
    Semin Oncol; 1995 Aug; 22(4 Suppl 9):70-4. PubMed ID: 7544029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I study of sequential administration of escalating doses of intravenous paclitaxel, oral topotecan, and fixed-dose oral etoposide in patients with solid tumors.
    Rocha Lima CM; Catapano CV; Pacheco D; Sherman CA; Oakhill G; Mushtaq C; Freeman KD; Green MR
    Cancer; 2004 Jun; 100(12):2671-9. PubMed ID: 15197811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Docetaxel-ifosfamide combination in patients with advanced breast cancer failing prior anthracycline-based regimens: results of a phase I-II study.
    Kosmas C; Tsavaris N; Mylonakis N; Tsakonas G; Gassiamis A; Skopelitis H; Polyzos A; Malamos N; Karabelis A
    J Chemother; 2007 Jun; 19(3):322-31. PubMed ID: 17594929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paclitaxel-ifosfamide-cisplatin as salvage chemotherapy in ovarian cancer patients pretreated with platinum compounds and paclitaxel.
    Polyzos A; Kosmas C; Tsavaris N; Toufexi H; Lagadas A; Gogas H; Giannakopoulos K; Kouraklis G; Griniatsos J; Felekouras E; Tsigris C; Nikiteas N; Papadopoulos O; Giannopoulos A
    Anticancer Res; 2007; 27(3B):1645-51. PubMed ID: 17595790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Salvage combined chemotherapy with paclitaxel, ifosfamide and nedaplatin for patients with advanced germ cell tumors.
    Nakamura T; Ueda T; Oishi M; Nakanishi H; Fujihara A; Naya Y; Hongo F; Kamoi K; Okihara K; Miki T
    Int J Urol; 2015 Mar; 22(3):288-93. PubMed ID: 25393104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.